Covered recipient · General Payments record
ANKIT N MEHTA
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$223,842.80
244 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $183,438.00 | 56 |
| Travel and Lodging | $20,828.20 | 101 |
| Consulting Fee | $15,069.00 | 3 |
| Food and Beverage | $4,498.60 | 83 |
| Education | $9.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $113,402.99 | 88 |
| AstraZeneca Pharmaceuticals LP | $105,874.78 | 140 |
| AKEBIA THERAPEUTICS INC | $2,295.00 | 1 |
| Amgen Inc. | $1,576.86 | 4 |
| Travere Therapeutics, Inc. | $499.43 | 5 |
| Chiesi USA, Inc. | $151.49 | 4 |
| GlaxoSmithKline, LLC. | $42.25 | 2 |
Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANKIT N MEHTA
NPI 1295944346 · CMS profile ID 149804
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295944346?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295944346?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295944346?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ANKIT N MEHTA, NPI 1295944346, CMS profile ID 149804, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 244 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295944346?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
244 matching records · $223,842.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 244.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $229.69 | 05/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105312097 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.14 | 05/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104313722 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.71 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105689199 | CMS |
| Chiesi USA, Inc. | $12.00 | 05/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151813447 | CMS |
| Chiesi USA, Inc. | $4.46 | 05/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151813451 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,900.00 | 05/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105541729 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.82 | 05/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104476538 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.99 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105427885 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,450.00 | 05/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105341971 | CMS |
| GENZYME CORPORATION | $121.86 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777958 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,450.00 | 05/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104703037 | CMS |
| GENZYME CORPORATION | $6,494.00 | 05/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777960 | CMS |
| GENZYME CORPORATION | $33.64 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777980 | CMS |
| GENZYME CORPORATION | $266.08 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777988 | CMS |
| GENZYME CORPORATION | $502.20 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777990 | CMS |
| GENZYME CORPORATION | $35.00 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777992 | CMS |
| GENZYME CORPORATION | $32.00 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777994 | CMS |
| GENZYME CORPORATION | $128.08 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777996 | CMS |
| AstraZeneca Pharmaceuticals LP | $813.15 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104672381 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.76 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105819037 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.16 | 04/30/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105838339 | CMS |
| AstraZeneca Pharmaceuticals LP | $274.08 | 04/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104664723 | CMS |
| AstraZeneca Pharmaceuticals LP | $232.75 | 04/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104756054 | CMS |
| AstraZeneca Pharmaceuticals LP | $60.46 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105452815 | CMS |
| AstraZeneca Pharmaceuticals LP | $38.05 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105474103 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,197.09 | 04/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105517217 | CMS |
| AstraZeneca Pharmaceuticals LP | $106.39 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105629862 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.69 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105889289 | CMS |
| GENZYME CORPORATION | $7,963.00 | 04/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777914 | CMS |
| GENZYME CORPORATION | $498.19 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777916 | CMS |
| GENZYME CORPORATION | $37.00 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777918 | CMS |
| GENZYME CORPORATION | $185.48 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777920 | CMS |
| GENZYME CORPORATION | $124.99 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777934 | CMS |
| GENZYME CORPORATION | $3,185.00 | 04/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777936 | CMS |
| GENZYME CORPORATION | $277.48 | 04/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777938 | CMS |
| GENZYME CORPORATION | $66.22 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777966 | CMS |
| AstraZeneca Pharmaceuticals LP | $9.00 | 04/18/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104691368 | CMS |
| GENZYME CORPORATION | $121.86 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777870 | CMS |
| GENZYME CORPORATION | $6,689.00 | 04/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777872 | CMS |
| GENZYME CORPORATION | $260.13 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777874 | CMS |
| GENZYME CORPORATION | $243.21 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777876 | CMS |
| GENZYME CORPORATION | $27.00 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777878 | CMS |
| GENZYME CORPORATION | $177.30 | 04/18/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777880 | CMS |
| GENZYME CORPORATION | $29.26 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777970 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,450.00 | 04/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105878063 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,450.00 | 04/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104372641 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,450.00 | 04/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104206447 | CMS |
| GENZYME CORPORATION | $93.94 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777922 | CMS |
| GENZYME CORPORATION | $7,963.00 | 04/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777924 | CMS |
| GENZYME CORPORATION | $207.11 | 04/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139777926 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $663,695.39 | 33 |
| PY2024 | Principal investigator | $509,022.94 | 88 |
| PY2023 | Principal investigator | $402,351.40 | 169 |
| PY2022 | Principal investigator | $122,375.40 | 9 |
| PY2021 | Principal investigator | $77,917.11 | 87 |
| PY2020 | Principal investigator | $121,712.00 | 10 |
| PY2019 | Principal investigator | $29,621.50 | 25 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
33 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GENZYME CORPORATION | $4,265.00 | 12/15/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119264 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $403.05 | 11/15/2025 | Non-covered Recipient Entity SCOTT AND WHITE MEDICAL CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A | No dispute reported | 06/30/2026 | 1190305123 |
| Principal investigator 1 | GENZYME CORPORATION | $10,967.00 | 11/10/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226119260 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,650.00 | 10/29/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | Fabry Disease Registry Protocol | No dispute reported | 06/30/2026 | 1226119266 |
| Principal investigator 1 | GENZYME CORPORATION | $9,904.00 | 10/27/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119249 |
| Principal investigator 1 | GENZYME CORPORATION | $7,250.00 | 09/15/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119234 |
| Principal investigator 1 | Amicus Therapeutics, Inc. | $2,600.00 | 08/27/2025 | Non-covered Recipient Entity Renal Disease Research Institute LLC | A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease | No dispute reported | 06/30/2026 | 1252319859 |
| Principal investigator 1 | Amicus Therapeutics, Inc. | $2,600.00 | 08/27/2025 | Non-covered Recipient Entity Renal Disease Research Institute LLC | A Study to Evaluate Migalastat in Fabry Subjects with Amenable GLA Variant and Renal Disease | No dispute reported | 06/30/2026 | 1252320203 |
| Principal investigator 1 | GENZYME CORPORATION | $21,110.00 | 08/25/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | ACT - POC clinical study - CD40L mAb - frexalimab | No dispute reported | 06/30/2026 | 1226119239 |
| Principal investigator 1 | GENZYME CORPORATION | $1,430.00 | 08/25/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226119245 |
| Principal investigator 1 | Amgen Inc. | $125,118.00 | 08/13/2025 | Non-covered Recipient Entity RENAL DISEASE RESEARCH INSTITUTE - LANDRY OFFICE | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246647141 |
| Principal investigator 1 | Celgene Corporation | $75,459.00 | 08/07/2025 | Non-covered Recipient Entity Baylor Scott And White Research Institute | A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) | No dispute reported | 06/30/2026 | 1222305790 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $752.78 | 07/28/2025 | Non-covered Recipient Entity Baylor Scott And White Research Institute | A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) | No dispute reported | 06/30/2026 | 1235998722 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $20,250.00 | 07/16/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | Fabry Disease Registry Protocol | No dispute reported | 06/30/2026 | 1226119253 |
| Principal investigator 1 | GENZYME CORPORATION | $6,490.00 | 07/14/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119232 |
| Principal investigator 1 | GENZYME CORPORATION | $7,686.00 | 06/23/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119227 |
| Principal investigator 1 | GENZYME CORPORATION | $6,261.00 | 06/09/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226119224 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,750.00 | 05/14/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | Fabry Disease Registry Protocol | No dispute reported | 06/30/2026 | 1226119271 |
| Principal investigator 1 | Chiesi USA, Inc. | $3,500.00 | 04/30/2025 | Non-covered Recipient Entity RENAL DISEASE RESEARCH INSTITUTE | Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients | No dispute reported | 06/30/2026 | 1234400312 |
| Principal investigator 1 | Chiesi USA, Inc. | $43,977.00 | 04/30/2025 | Non-covered Recipient Entity RENAL DISEASE RESEARCH INSTITUTE | Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients | No dispute reported | 06/30/2026 | 1234400316 |
| Principal investigator 1 | GENZYME CORPORATION | $2,535.00 | 04/28/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226119217 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,042.70 | 04/23/2025 | Non-covered Recipient Entity AVICENNA DM CLINICAL RESEARCH | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185538651 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,914.28 | 04/15/2025 | Non-covered Recipient Entity RENAL DISEASE RESEARCH INSTITUTE | An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i | No dispute reported | 06/30/2026 | 1190309954 |
| Principal investigator 1 | GENZYME CORPORATION | $14,552.00 | 04/07/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119211 |
| Principal investigator 1 | GENZYME CORPORATION | $3,315.00 | 03/17/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy | No dispute reported | 06/30/2026 | 1226119207 |
| Principal investigator 1 | GENZYME CORPORATION | $6,938.00 | 02/18/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119200 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,575.00 | 02/14/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | Fabry Disease Registry Protocol | No dispute reported | 06/30/2026 | 1226119214 |
| Principal investigator 1 | GENZYME CORPORATION | $3,333.95 | 02/10/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119204 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $45,390.00 | 01/30/2025 | Non-covered Recipient Entity BAYLOR RESEARCH INSTITUTE | A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A | No dispute reported | 06/30/2026 | 1190300191 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $158,529.79 | 01/15/2025 | Non-covered Recipient Entity DALLAS NEPHROLOGY ASSOCIATES | An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i | No dispute reported | 06/30/2026 | 1190304567 |
| Principal investigator 1 | GENZYME CORPORATION | $3,934.00 | 01/13/2025 | Non-covered Recipient Entity Renal Disease Reasearch Institute L | A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults With Fabry Disease Who Are Treatment-naive or Untreated for at Least 6 Months | No dispute reported | 06/30/2026 | 1226119196 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,242.20 | 01/08/2025 | Non-covered Recipient Entity RENAL DISEASE RESEARCH INSTITUTE | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185538653 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $970.64 | 01/01/2025 | Non-covered Recipient Entity SCOTT AND WHITE MEDICAL CENTER | A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated A | No dispute reported | 06/30/2026 | 1190304737 |